[go: up one dir, main page]

MX2023001776A - Anticuerpos contra ilt2 y uso de los mismos. - Google Patents

Anticuerpos contra ilt2 y uso de los mismos.

Info

Publication number
MX2023001776A
MX2023001776A MX2023001776A MX2023001776A MX2023001776A MX 2023001776 A MX2023001776 A MX 2023001776A MX 2023001776 A MX2023001776 A MX 2023001776A MX 2023001776 A MX2023001776 A MX 2023001776A MX 2023001776 A MX2023001776 A MX 2023001776A
Authority
MX
Mexico
Prior art keywords
ilt2
methods
antibodies against
antibodies
present disclosure
Prior art date
Application number
MX2023001776A
Other languages
English (en)
Inventor
Tehila Ben-Moshe
Yair Sapir
Ilana Mandel
Avidor Shulman
Tsuri Peretz
Ziv Dana Haves
Ilana Goldshtein
Dror Alishekevitz
Anna Fridman-Dror
Motti Hakim
Original Assignee
Biond Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2020/050889 external-priority patent/WO2021028921A1/en
Application filed by Biond Biologics Ltd filed Critical Biond Biologics Ltd
Publication of MX2023001776A publication Critical patent/MX2023001776A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona anticuerpos monoclonales anti-ILT2 o fragmentos de unión a antígeno de los mismos, así como composiciones farmacéuticas que comprenden los mismos y métodos para producir los mismos. También se proporcionan métodos para tratar el cáncer utilizando los anticuerpos o composiciones de la presente divulgación. También se proporcionan métodos para la selección de pacientes.
MX2023001776A 2020-08-12 2021-08-11 Anticuerpos contra ilt2 y uso de los mismos. MX2023001776A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IL2020/050889 WO2021028921A1 (en) 2019-08-12 2020-08-12 Antibodies against ilt2 and use thereof
US202163145604P 2021-02-04 2021-02-04
US202163149371P 2021-02-15 2021-02-15
PCT/IB2021/057414 WO2022034524A2 (en) 2020-08-12 2021-08-11 Antibodies against ilt2 and use thereof

Publications (1)

Publication Number Publication Date
MX2023001776A true MX2023001776A (es) 2023-03-10

Family

ID=80223922

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001776A MX2023001776A (es) 2020-08-12 2021-08-11 Anticuerpos contra ilt2 y uso de los mismos.

Country Status (14)

Country Link
US (1) US12071479B2 (es)
EP (1) EP4196227A2 (es)
JP (1) JP2023537396A (es)
KR (1) KR20230058074A (es)
CN (1) CN116096756A (es)
AU (1) AU2021325430A1 (es)
BR (1) BR112023002301A2 (es)
CA (1) CA3190634A1 (es)
CO (1) CO2023002375A2 (es)
IL (1) IL300588A (es)
MX (1) MX2023001776A (es)
TW (1) TW202221035A (es)
WO (1) WO2022034524A2 (es)
ZA (1) ZA202302392B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002579A2 (pt) 2019-08-12 2022-06-14 Biond Biologics Ltd Anticorpos contra ilt2 e uso dos mesmos
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
CN116082500B (zh) * 2022-12-09 2023-08-22 珠海重链生物科技有限公司 抗SARS-CoV-2抗体nCoV1和nCoV2及其应用
WO2024207855A1 (zh) * 2023-04-04 2024-10-10 成都优洛生物科技有限公司 抗lilrb1抗体或其抗原结合片段、制备方法和用途
US20250019441A1 (en) 2023-07-11 2025-01-16 Biond Biologics Ltd. Treatment of cancer with anti-ilt2 antibodies
TW202525855A (zh) * 2023-08-31 2025-07-01 美商艾克塞里克斯公司 Ｉｌｔ２結合劑及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
CN104645327A (zh) 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
US10316094B2 (en) 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
LT3405495T (lt) 2016-01-21 2021-08-10 Innate Pharma Inhibitorių kelių neutralizavimas limfocituose
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
US20210122819A1 (en) 2018-01-18 2021-04-29 Adanate, Inc. Anti-lilrb antibodies and uses thereof
KR20210027436A (ko) * 2018-06-29 2021-03-10 베링거 인겔하임 인터내셔날 게엠베하 자가면역 질환을 치료하는데 사용하기 위한 항-cd40 항체
EP3827020A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
JP2022516140A (ja) 2018-12-26 2022-02-24 インネート・ファルマ 白血球免疫グロブリン様受容体２中和抗体
BR112022002579A2 (pt) 2019-08-12 2022-06-14 Biond Biologics Ltd Anticorpos contra ilt2 e uso dos mesmos
CN114901689A (zh) 2019-10-14 2022-08-12 先天制药公司 用ilt-2抑制剂治疗癌症
EP4071172A4 (en) 2019-12-23 2023-10-18 Lg Chem, Ltd. ANTI-LILRB1 ANTIBODIES AND ITS USES
PE20221894A1 (es) 2020-05-01 2022-12-13 Ngm Biopharmaceuticals Inc Agentes de union a ilt y metodos para su uso

Also Published As

Publication number Publication date
WO2022034524A3 (en) 2022-04-28
KR20230058074A (ko) 2023-05-02
JP2023537396A (ja) 2023-08-31
US20220048991A1 (en) 2022-02-17
AU2021325430A1 (en) 2023-04-20
WO2022034524A2 (en) 2022-02-17
ZA202302392B (en) 2025-05-28
CN116096756A (zh) 2023-05-09
EP4196227A2 (en) 2023-06-21
CA3190634A1 (en) 2022-02-17
CO2023002375A2 (es) 2023-03-27
US12071479B2 (en) 2024-08-27
IL300588A (en) 2023-04-01
TW202221035A (zh) 2022-06-01
BR112023002301A2 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
ZA202202363B (en) Antibodies against ilt2 and use thereof
ZA202302392B (en) Antibodies against ilt2 and use thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2022013163A (es) Anticuerpo contra nectin-4 y aplicacion del mismo.
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
MX2024010630A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
SA523440622B1 (ar) أجسام مضادة
ZA202006318B (en) Anti-dll3 antibodies and uses thereof
PH12021553289A1 (en) Anti-tissue factor antibody-drug conjugates and related methods
ZA202008095B (en) Humanized antibodies against psma
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
WO2021067633A3 (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
MX2025010217A (es) Anticuerpos multiespecificos anti-cd3 y metodos de uso
EA202092151A1 (ru) Антитела
EA202092121A1 (ru) Антитела против cd73 и их применения
MX2024009326A (es) Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.